Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the most promising antibiotics in development for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections are Johnson & Johnson/Basilea's ceftobiprole (a cephalosporin) and Theravance/Astellas's telavancin (a lipoglycopeptide).

The new Pharmacor report Methicillin-Resistant Staphylococcus aureus finds that an active pipeline of novel glycopeptides and anti-MRSA cephalosporins will generate nearly $300 million in sales by 2016. MRSA infections represent the most important resistant Gram-positive infection market, and it is expected to expand during the next decade, rising from approximately $550 million in 2006 to nearly $750 million in 2016.

The report also finds that the late-stage pipeline comprises mostly parenteral agents that target hospital-acquired MRSA infections, leaving significant commercial opportunity for oral agents that can facilitate stepdown therapy for hospital-acquired MRSA infections -- such a therapy would reduce hospital stay and associated healthcare costs. In addition, novel oral MRSA agents will provide important therapeutic alternatives for the growing number of community-acquired MRSA infections. The increasing prevalence of multidrug-resistant MRSA in both the hospital and community settings will drive continued need for novel therapies with high efficacy in the face of existing resistance mechanisms. In particular, the expansion of an aging population with increased likelihood of hospitalization and risk of MRSA infections will fuel an increase in the number of MRSA infections and in the size of the MRSA market in the world's major pharmaceutical markets -- the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan.

"The use of antibiotics will remain an important target for cost containment as hospitals are increasingly challenged to reduce pharmacy expenditures while maintaining quality of care," said Decision Resources Analyst Danielle Drayton, Ph.D. "As a result, new premium-priced agents still face significant hurdles in convincing hospital pharmacy directors of the cost-benefit and clinical advantages of new antibiotics compared with relatively safe and effective lower-priced generics."

About MRSA

Antibiotic resistance in the hospital setting has risen dramatically over the past 10-15 years and is a major source of concern for clinicians. MRSA is one of the most common antibiotic-resistant pathogens in hospitals, and it is a formidable pathogen to treat because it is resistant to most classes of antibiotics. Highly publicized for staph infections spreading through schools, prisons, and athletic facilities, the concern regarding MRSA is due to the fact that it is resistant to first-line penicillin and often also to other antibiotics.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
+1-781-296-2563, emarshall@dresources.com

Driven By Genentech/Roche/Chugai's Avastin, the Ovarian Cancer Drug Market Will More Than Triple to $1.6 Billion by 2016

View Now